Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term gynecologic-oncology-group. Found 25 abstracts

no pagination
Bodurka DC, Deavers MT, Tian CQ, Sun CC, Malpica A, Coleman RL, Lu KH, Sood AK, Birrer MJ, Ozols R, Baergen R, Emerson RE, Steinhoff M, Behmaram B, Rasty G, Gershenson DM. Reclassification of serous ovarian carcinoma by a 2-tier system. Cancer. 2012 Jun;118(12):3087-94.   PMCID: *
Sill MW, Rubinstein L, Litwin S, Yothers G. A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage Phase II clinical trials. Clinical Trials. 2012 Aug;9(4):385-95.   PMCID: PMC 3598604
Bell D, Berchuck A, Birrer M, Chien J, Cramer DW, Dao F, Dhir R, DiSaia P, Gabra H, Glenn P, Godwin AK, Gross J, Hartmann L, Huang M, Huntsman DG, Iacocca M, Imielinski M, Kalloger S, Karlan BY, Levine DA, Mills GB, Morrison C, Mutch D, Olvera N, Orsulic S, Park K, Petrelli N, Rabeno B, Rader JS, Sikic BI, Smith-McCune K, Sood AK, Bowtell D, Penny R, Testa JR, Chang K, Dinh HH, Drummond JA, Fowler G, Gunaratne P, Hawes AC, Kovar CL, Lewis LR, Morgan MB, Newsham IF, Santibanez J, Reid JG, Trevino LR, Wu YQ, Wang M, Muzny DM, Wheeler DA, Gibbs RA, Getz G, Lawrence MS, Cibulskis K, Sivachenko AY, Sougnez C, Voet D, Wilkinson J, Bloom T, Ardlie K, Fennell T, Baldwin J, Gabriel S, Lander ES, Ding L, Fulton RS, Koboldt DC, McLellan MD, Wylie T, Walker J, O'Laughlin M, Dooling DJ, Fulton L, Abbott R, Dees ND, Zhang Q, Kandoth C, Wendl M, Schierding W, Shen D, Harris CC, Schmidt H, Kalicki J, Delehaunty KD, Fronick CC, Demeter R, Cook L, Wallis JW, Lin L, Magrini VJ, Hodges JS, Eldred JM, Smith SM, Pohl CS, Vandin F, Raphael BJ, Weinstock GM, Mardis R, Wilson RK, Meyerson M, Winckler W, Verhaak RG, Carter SL, Mermel CH, Saksena G, Nguyen H, Onofrio RC, Hubbard D, Gupta S, Crenshaw A, Ramos AH, Chin L, Protopopov A, Zhang JH, Kim TM, Perna I, Xiao Y, Zhang H, Ren G, Sathiamoorthy N, Park RW, Lee E, Park PJ, Kucherlapati R, Absher DM, Waite L, Sherlock G, Brooks JD, Li JZ, Xu J, Myers RM, Laird PW, Cope L, Herman JG, Shen H, Weisenberger DJ, Noushmehr H, Pan F, Triche T, Berman BP, Van den Berg DJ, Buckley J, Baylin SB, Spellman PT, Purdom E, Neuvial P, Bengtsson H, Jakkula LR, Durinck S, Han J, Dorton S, Marr H, Choi YG, Wang V, Wang NJ, Ngai J, Conboy JG, Parvin B, Feiler HS, Speed TP, Gray JW, Socci ND, Liang Y, Taylor BS, Schultz N, Borsu L, Lash AE, Brennan C, Viale A, Sander C, Ladanyi M, Hoadley KA, Meng S, Du Y, Shi Y, Li L, Turman YJ, Zang D, Helms EB, Balu S, Zhou X, Wu J, Topal MD, Hayes DN, Perou CM, Zhang JN, Wu CJ, Shukla S, Sivachenko A, Jing R, Liu Y, Noble M, Carter H, Kim D, Karchin R, Korkola JE, Heiser LM, Cho RJ, Hu Z, Cerami E, Olshen A, Reva B, Antipin Y, Shen R, Mankoo P, Sheridan R, Ciriello G, Chang WK, Bernanke JA, Haussler D, Benz CC, Stuart JM, Benz SC, Sanborn JZ, Vaske CJ, Zhu J, Szeto C, Scott GK, Yau C, Wilkerson MD, Zhang N, Akbani R, Baggerly KA, Yung WK, Weinstein JN, Shelton T, Grimm D, Hatfield M, Morris S, Yena P, Rhodes P, Sherman M, Paulauskis J, Millis S, Kahn A, Greene JM, Sfeir R, Jensen MA, Chen J, Whitmore J, Alonso S, Jordan J, Chu A, Barker A, Compton C, Eley G, Ferguson M, Fielding P, Gerhard DS, Myles R, Schaefer C, Shaw KR, Vaught J, Vockley JB, Good PJ, Guyer MS, Ozenberger B, Peterson J, Thomson E, Canc Genome Atlas Res Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011 Jun;474(7353):609-15.   PMCID: PMC3163504
Burger RA. Overview of anti-angiogenic agents in development for ovarian cancer. Gynecologic Oncology. 2011 Apr;121(1):230-8.   PMCID: not NIH funded
Greer BE, Koh WJ, Abu-Rustum NR, Apte SM, Campos SM, Chan J, Cho KR, Copeland L, Crispens MA, DuPont N, Eifel PJ, Gaffney DK, Huh WK, Kapp DS, Lurain JR, Martin L, Morgan MA, Morgan RJ, Mutch D, Remmenga SW, Reynolds RK, Small W, Teng N, Valea FA. Cervical Cancer. Journal of the National Comprehensive Cancer Network. 2010 Dec;8(12):1388-416.   PMCID: not NIH funded
Mabuchi S, Kawase C, Altomare DA, Morishige K, Hayashi M, Sawada K, Ito K, Terai Y, Nishio Y, Klein-Szanto AJ, Burger RA, Ohmichi M, Testa JR, Kimura T. Vascular Endothelial Growth Factor Is a Promising Therapeutic Target for the Treatment of Clear Cell Carcinoma of the Ovary. Molecular Cancer Therapeutics. 2010 Aug;9(8):2411-22.   PMCID: PMC2941981 [Available on 2011/8/1]
Mabuchi S, Kawase C, Altomare DA, Morishige K, Sawada K, Hayashi M, Tsujimoto M, Yamoto M, Klein-Szanto AJ, Schilder RJ, Ohmichi M, Testa JR, Kimura T. mTOR Is a Promising Therapeutic Target Both in Cisplatin-Sensitive and Cisplatin-Resistant Clear Cell Carcinoma of the Ovary. Clinical Cancer Research. 2009 Sep;15(17):5404-13.   PMCID: PMC2743856
Ozols RF, Bookman MA, Young RC, Du Bois A, Pfisterer J, Reuss A. Intraperitoneal cisplatin therapy in ovarian cancer: Comparison with standard intravenous carboplatin and paclitaxel. GYNECOLOGIC ONCOLOGY. 2006 Oct;103(1):1-6.
Bookman MA. Standard treatment in advanced ovarian cancer in 2005: the state of the art. International Journal of Gynecological Cancer. 2005 Nov 03;15:212-20.
Bookman MA. Is there still a role for hormonal therapy?. International Journal of Gynecological Cancer. 2005 Nov 03;15:291-7.
Ozols RF. NICE guidelines for ovarian cancer: Recommendations versus standard care. Cancer Investigation. 2004 Jan;22 (5):815-7.
Ozols RF. Chemotherapy for ovarian cancer: Beyond paclitaxel plus carboplatin. Cancer Journal from Scientific American. 1999 Nov;5(6):336-8.
Ozols RF, Gore M, Trope C, Grenman S. Intraperitoneal treatment and dose-intense therapy in ovarian cancer. Annals of Oncology. 1999 Jan;10:59-64.
Schilder RJ, Johnson S, Gallo J, Kindsfather S, Rogers B, Bookman MA, Millenson MM, Boente M, Rosenblum N, Litwin S, Ozols RF. Phase I trial of multiple cycles of high-dose chemotherapy supported by autologous peripheral-blood stem cells. Journal of Clinical Oncology. 1999 Jul;17(7):2198-207.
McGuire WP, Ozols RF. Chemotherapy of advanced ovarian cancer. Seminars in Oncology. 1998 Jun;25(3):340-8.
Greven KM, Corn BW, Case D, Purser P, Lanciano RM. Which prognostic factors influence the outcome of patients with surgically staged endometrial cancer treated with adjuvant radiation?. International Journal of Radiation Oncology Biology Physics. 1997 Sep;39(2):413-8.
Ozols RF. Future directions in the chemotherapy of ovarian cancer. Seminars in Oncology. 1997 Oct;24(5):86-90.
Ozols RF. Controversies in the management of ovarian cancer. International Journal of Gynecological Cancer. 1997 May;7:27-32.
Ozols RF, Vermorken JB. Chemotherapy of advanced ovarian cancer: Current status and future directions. Seminars in Oncology. 1997 Feb;24(1):S1-S9.
Kotz KW, Schilder RJ. High-Dose Chemotherapy and Hematopoietic Progenitor-Cell Support for Patients with Epithelial Ovarian-Cancer. Seminars in Oncology. 1995 Jun;22(3):250-62.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term gynecologic-oncology-group

gynecologic-oncology-group cyclophosphamide carcinoma carboplatin cisplatin randomized trial phase-ii phase-ii trial chemotherapy ovarian cancer paclitaxel randomized-trial therapy cancer phase-iii bevacizumab adenocarcinoma clear-cell carcinoma tumors platinum-resistant in-vitro epithelial ovarian breast-cancer 1st-line treatment colony-stimulating factor recurrent stage-iii tamoxifen doxorubicin survival phase-iii trial bone-marrow transplantation expression platinum prognosis resistant akt external irradiation apoptosis paclitaxel taxol corpus of-the-literature responses mutational ii epithelial ovarian-cancer intraperitoneal cisplatin lung-cancer persistent ovarian-cancer NCCN Guidelines Oncology chemotherapy regimens standard therapy postoperative vaginal irradiation single-agent carboplatin primary peritoneal cancer whole abdomen irradiation fibroblast-growth-factor rapamycin intensive therapy Ovarian cancer weekly paclitaxel radiation therapy NCCN Clinical Practice Guidelines uterine stage-iii ovarian intergroup trial radical hysterectomy cancer statistics induced estrogen replacement therapy dose intensity uterine cervix positron-emission-tomography 2008 rbes sa-pch10 cisplatin-cyclophosphamide neoplasms transplantation support cell high-throughput annotation cancer-cells vascular space invasion hexamethylmelamine universal grading system mammalian target cell lung-cancer squamous-cell-carcinoma hysterectomy combination chemotherapy grade serous peripheral stem cell Anti-angiogenic therapy cell-proliferation angiogenesis autologous bone marrow transplantation hybrid selection solid tamoxifen therapy susceptibility gene p53 high-dose mitoxantrone paclitaxel-cisplatin Bevacizumab somatic adjuvant therapy hormone therapy pelvic radiation-therapy platinum-resistant disease endometrial carcinoma human papillomavirus imatinib mesylate surgical staging cervical cancer intravenous braf risk factors multiple outcomes cross-talk bone-marrow long-term cytoreductive surgery intraperitoneal therapy 1961 han ea-journal of chronic diseases-v13-p346 brca mutation carriers peripheral-blood inhibitors inhibition inhibitor rad001 kras end-points new standard clinical-trials stage intraperitoneal chemotherapy phase-i-ii endothelial-cells serous histology ovarian cancer-2-tier grading system-FIGO grading tumor-growth Tyrosine kinase Obstetrics & Gynecology tyrosine kinase inhibitor intensity analysis trial driver mutations designs clinical 2nd-line therapy adjuvant irradiation
Last updated on Friday, January 03, 2020